Single-cell RNA sequencing for engineering and studying human islets
Its triple GIP/GLP-1/glucagon agonist mechanism produced the most striking weight-loss numbers ever reported in a Phase 2 trial of an injectable peptide, and its broad TRIUMPH Phase 3 program is poised to expand understanding of how triple receptor modulation affects obesity, diabetes, liver disease, cardiovascular risk, sleep apnea, and musculoskeletal health
Weight changes became more significant over time
In published mouse studies, 50 mg/kg IP twice daily for 28 days is the highest-dose, longest-duration regimen reported in peer-reviewed literature
In animal studies, BPC157 helped repaired tendons get stronger, and TB500 reduced the scar tissue that can limit your movement after an operation
It helps with actin upregulation to move cells to injury sites and speed up tissue repair